File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Therapeutic Strategies against Epstein-Barr Virus-Associated Cancers Using Proteasome Inhibitors

TitleTherapeutic Strategies against Epstein-Barr Virus-Associated Cancers Using Proteasome Inhibitors
Authors
Hui, KFTam, KPChiang, AKS
KeywordsApoptosis
Cell cycle
Epstein-Barr virus
Epstein-Barr virus nuclear antigen (EBNA)-3C
Lytic reactivation
Issue Date2017
PublisherMolecular Diversity Preservation International (MDPI) AG.. The Journal's web site is located at http://www.mdpi.com/journal/viruses
Citation
Viruses, 2017, v. 9 n. 1, article no. 352 How to Cite?
DOI: http://dx.doi.org/10.3390/v9110352
AbstractEpstein-Barr virus (EBV) is closely associated with several lymphomas (endemic Burkitt lymphoma, Hodgkin lymphoma and nasal NK/T-cell lymphoma) and epithelial cancers (nasopharyngeal carcinoma and gastric carcinoma). To maintain its persistence in the host cells, the virus manipulates the ubiquitin-proteasome system to regulate viral lytic reactivation, modify cell cycle checkpoints, prevent apoptosis and evade immune surveillance. In this review, we aim to provide an overview of the mechanisms by which the virus manipulates the ubiquitin-proteasome system in EBV-associated lymphoid and epithelial malignancies, to evaluate the efficacy of proteasome inhibitors on the treatment of these cancers and discuss potential novel viral-targeted treatment strategies against the EBV-associated cancers.
Persistent Identifierhttp://hdl.handle.net/10722/264236
ISSN
1999-4915
2023 Impact Factor: 3.8
2023 SCImago Journal Rankings: 1.140
ISI Accession Number ID
WOS:000416810300042

 

DC FieldValueLanguage
dc.contributor.authorHui, KF-
dc.contributor.authorTam, KP-
dc.contributor.authorChiang, AKS-
dc.date.accessioned2018-10-22T07:51:43Z-
dc.date.available2018-10-22T07:51:43Z-
dc.date.issued2017-
dc.identifier.citationViruses, 2017, v. 9 n. 1, article no. 352-
dc.identifier.issn1999-4915-
dc.identifier.urihttp://hdl.handle.net/10722/264236-
dc.description.abstractEpstein-Barr virus (EBV) is closely associated with several lymphomas (endemic Burkitt lymphoma, Hodgkin lymphoma and nasal NK/T-cell lymphoma) and epithelial cancers (nasopharyngeal carcinoma and gastric carcinoma). To maintain its persistence in the host cells, the virus manipulates the ubiquitin-proteasome system to regulate viral lytic reactivation, modify cell cycle checkpoints, prevent apoptosis and evade immune surveillance. In this review, we aim to provide an overview of the mechanisms by which the virus manipulates the ubiquitin-proteasome system in EBV-associated lymphoid and epithelial malignancies, to evaluate the efficacy of proteasome inhibitors on the treatment of these cancers and discuss potential novel viral-targeted treatment strategies against the EBV-associated cancers.-
dc.languageeng-
dc.publisherMolecular Diversity Preservation International (MDPI) AG.. The Journal's web site is located at http://www.mdpi.com/journal/viruses-
dc.relation.ispartofViruses-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectApoptosis-
dc.subjectCell cycle-
dc.subjectEpstein-Barr virus-
dc.subjectEpstein-Barr virus nuclear antigen (EBNA)-3C-
dc.subjectLytic reactivation-
dc.titleTherapeutic Strategies against Epstein-Barr Virus-Associated Cancers Using Proteasome Inhibitors-
dc.typeArticle-
dc.identifier.emailHui, KF: kfhui@hku.hk-
dc.identifier.emailChiang, AKS: chiangak@hku.hk-
dc.identifier.authorityChiang, AKS=rp00403-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3390/v9110352-
dc.identifier.pmid29160853-
dc.identifier.scopuseid_2-s2.0-85035334003-
dc.identifier.hkuros295016-
dc.identifier.volume9-
dc.identifier.issue1-
dc.identifier.spagearticle no. 352-
dc.identifier.epagearticle no. 352-
dc.identifier.isiWOS:000416810300042-
dc.publisher.placeSwitzerland-
dc.identifier.issnl1999-4915-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats